Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Mankind Pharma Ltd

MANKIND:NSI

Mankind Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,667.35
  • Today's Change42.35 / 1.61%
  • Shares traded386.98k
  • 1 Year change+52.86%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 10:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans women’s health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

  • Revenue in INR (TTM)106.50bn
  • Net income in INR19.63bn
  • Incorporated1991
  • Employees19.54k
  • Location
    Mankind Pharma Ltd262, Okhla Industrial Estate, Phase-IIINEW DELHI 110020IndiaIND
  • Phone+91 1 147476600
  • Fax+91 1 146541382
  • Websitehttps://www.mankindpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MANKIND:NSI since
announced
Transaction
value
Bharat Serums & Vaccines LtdDeal completed25 Jul 202425 Jul 2024Deal completed26.57%1.64bn
Data delayed at least 15 minutes, as of Oct 31 2024 10:21 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abbott India Ltd59.28bn12.39bn603.63bn3.81k48.72--46.0310.18583.08583.082,789.54--------15,541,480.00--20.92--28.5945.2844.2020.9017.26--119.46--77.069.359.7226.5221.6831.0852.32
Alkem Laboratories Ltd127.32bn20.54bn692.95bn17.28k33.73--29.105.44171.81171.811,064.87--------7,369,150.00--11.88--17.5062.2159.2616.2913.94--9.12--29.829.2111.4882.4718.75-13.3020.11
Aurobindo Pharma Ltd297.18bn35.21bn816.11bn8.80k23.37--16.042.7560.1260.12507.19--------33,782,390.00--9.24--13.4357.8753.3011.8412.72--13.17--8.6416.688.1964.626.0617.9612.47
Lupin Ltd207.97bn22.64bn984.58bn21.87k43.60--29.874.7349.5049.50454.84--------9,510,284.00--1.43--2.2267.5858.5211.002.04--9.07--75.0320.256.41345.1530.18-1.179.86
Zydus Lifesciences Ltd206.15bn41.69bn991.49bn26.24k23.87--19.904.8141.2841.51204.01--------7,856,441.00--9.05--14.0170.2261.1520.2914.33------16.4813.408.2395.2515.72-3.03-3.04
Dr Reddy's Laboratories Ltd289.49bn55.65bn1.04tn26.34k18.73--14.743.6066.7466.74347.18--------10,989,370.00--11.37--16.0270.8065.8619.2214.63--36.60--15.9113.5412.6423.7523.3926.7814.87
Mankind Pharma Ltd106.50bn19.63bn1.05tn19.54k53.72--43.709.8948.9148.91265.43--------5,450,142.00--------69.93--18.69----90.42----18.12--49.23------
Torrent Pharmaceuticals Ltd112.25bn18.02bn1.06tn14.92k58.9314.1540.839.4653.2553.25331.63221.720.75251.226.357,525,369.0012.088.3417.9513.0375.5271.7816.0613.180.74449.320.294161.6511.516.9333.0230.58-8.1726.93
Cipla Ltd265.12bn44.75bn1.15tn27.76k25.604.0420.734.3255.3955.39328.19351.200.8031.585.089,549,060.0013.5810.0916.4412.4067.0158.6316.9212.662.8269.410.01621.3913.289.5147.1021.9620.6834.08
Divi's Laboratories Ltd81.85bn16.74bn1.56tn17.50k93.36--76.0119.0963.0563.05308.33--------4,677,143.00--16.55--18.2259.7656.2420.4526.38------34.320.99769.66-12.253.416.4713.40
Data as of Oct 31 2024. Currency figures normalised to Mankind Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.08%Per cent of shares held by top holders
HolderShares% Held
Axis Asset Management Co. Ltd.as of 30 Sep 20243.98m0.99%
The Vanguard Group, Inc.as of 30 Sep 20243.42m0.85%
SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Aug 20243.36m0.84%
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 20243.17m0.79%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 20243.03m0.76%
Capital Research & Management Co. (World Investors)as of 03 Oct 20242.97m0.74%
Canada Pension Plan Investment Boardas of 31 Mar 20242.29m0.57%
BlackRock Fund Advisorsas of 03 Oct 20242.25m0.56%
Tata AIA Life Insurance Co. Ltd.as of 30 Sep 20242.03m0.51%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 20241.90m0.47%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.